4.3 Article

Comparison of intravenous and subcutaneous exposure supporting dose selection of subcutaneous belimumab systemic lupus erythematosus Phase 3 program

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Pharmacology & Pharmacy

The pharmacokinetics and safety profiles of belimumab after single subcutaneous and intravenous doses in healthy Japanese volunteers

Y. Shida et al.

JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2014)

Article Pharmacology & Pharmacy

Population Pharmacokinetics of Belimumab Following Intravenous Administration in Patients With Systemic Lupus Erythematosus

Herbert Struemper et al.

JOURNAL OF CLINICAL PHARMACOLOGY (2013)

Article Pharmacology & Pharmacy

Bioavailability, Pharmacokinetics, and Safety of Belimumab Administered Subcutaneously in Healthy Subjects

Wendy W. Cai et al.

CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2013)

Review Pharmacology & Pharmacy

Population Pharmacokinetics of Therapeutic Monoclonal Antibodies

Nathanael L. Dirks et al.

CLINICAL PHARMACOKINETICS (2010)

Review Immunology

Clinical Ramifications of the MHC Family Fc Receptor FcRn

Derry C. Roopenian et al.

JOURNAL OF CLINICAL IMMUNOLOGY (2010)

Review Pharmacology & Pharmacy

Mechanistic Basis of Using Body Size and Maturation to Predict Clearance in Humans

Brian J. Anderson et al.

DRUG METABOLISM AND PHARMACOKINETICS (2009)

Review Medicine, Research & Experimental

The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus

Michael P. Cancro et al.

JOURNAL OF CLINICAL INVESTIGATION (2009)

Review Pharmacology & Pharmacy

Monoclonal Antibody Pharmacokinetics and Pharmacodynamics

W. Wang et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)